Objective: To investigate the significance of the presence or absence of the thymus in the development of pulmonary hypertension (PH) following monocrotaline (MCT) administration, the degree of MCT-induced PH (MCT-PH) in athymic nude (F344/N Jcl-rnu) rats was compared with that in their euthymic (rnu/+) littermates. Methods: Histopathological studies of the lung in terms of interstitial edema, congestion, thickening of the alveolar wall, inflammatory cell infiltration and degeneration of arteries were performed by staining with hematoxylin-eosin (HE), elastin van Gieson and Masson’s trichrome. The medial wall thickness of the small pulmonary arteries and the weight ratio of the right ventricular free wall (RV) to that of the left ventricle plus septum [RV/(LV + S) weight ratio] were used as indices of the degree of PH. Toluidine blue staining was performed to estimate the number of the mast cells in the lung interstitium. Results: Interstitial edema was significantly severer in MCT- injected euthymic rats than in MCT-injected athymic nude rats (p < 0.01); in contrast, the thickening of the alveolar wall was severer in MCT-injected athymic nude rats than in MCT-injected euthymic rats (p < 0.05). The degree of MCT-PH, as determined by the medial wall thickness of the small pulmonary arteries and RV/(LV + S) weight ratio in MCT-injected athymic nude rats, was significantly severer than in MCT-injected euthymic rats (p < 0.05 and p < 0.01, respectively). The number of mast cells was significantly greater in MCT-injected athymic nude rats than in MCT-injected euthymic rats (p < 0.01). The degree of the medial wall thickness of the small pulmonary arteries was significantly correlated with RV/(LV + S) weight ratio (p < 0.05) as well as with the number of mast cells in MCT-injected rats. Conclusions: Athymic nude rats developed severer PH than euthymic rats along with a greater number of mast cells and severer histopathological changes, such as thickening of the alveolar wall. Mast cell proliferation was considered to play a pivotal role in the development of PH in MCT-PH.

Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D: Mechanisms and pathology of monocrotaline toxicity. Crit Rev Toxicol 1992;22:307–325.
Chesney CF, Allen JR: Animal model: pulmonary hypertension, cor pulmonale and endocardial fibroelastosis in monocrotaline-intoxicated nonhuman primates. Am J Pathol 1973;70:489–492.
Miyata M, Sakuma F, Yoshimura A, Ishikawa H, Nishimaki T, Kasukawa R: Pulmonary hypertension in rats. 1. Role of bromodeoxyuridine-positive mononuclear cells and alveolar macrophages. Int Arch Allergy Immunol 1995;108:281–296.
Miyata M, Sakuma F, Yoshimura A, Ishikawa H, Nishimaki T, Kasukawa R: Pulmonary hypertension in rats. 2. Role of interleukin-6. Int Arch Allergy Immunol 1995;108:287–291.
Miyata M, Ueno Y, Sekine H, Ito O, Sakuma F, Koike H, Nishio S, Nishimaki T, Kasukawa R: Effect of beraprost sodium, a stable prostacycline analogue, in development of monocrotaline-induced pulmonary hypertension. J Cardiolvasc Pharmacol 1996;27:20–26.
Sakuma F, Miyata M, Kasukawa R: Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats. Lung 1999;177:77–88.
Sone Y, Serikov VB, Staub NC Sr: Intravascular macrophage depletion attenuates endotoxin lung injury in anesthetized sheep. J Appl Physiol 1999;87:1354–1359.
Speich RR, Jenni R, Opravil M, Pfab M, Russi EW: Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268–1271.
Mette SA, Palevsky HI, Pietra GG, Williams TM, Bruder E, Prestipino AJ, Patric AM, Wirth JA: Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992;145:11196–2000.
Kanai Y, Hori S, Tanaka T, Yasuoka M, Watanabe K, Aikawa N, Hosoda Y: Role of 5-hydroxytryptamine in the progression of monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 1993;27:1619–1623.
Schwinzer R, Hedrich HJ, Wonigeit K: T cell differentiation in athymic nude rats (rnu/rnu): Demonstration of a distorted T cell subset structure by flow cytometry analysis. Eur J Immunol 1989;19:1841–1847.
Hayashi Y, Hussa JF, Lalich JJ: Cor pulmonale in rats. Lab Invest 1967;16:875–881.
Ghodsi F, Will JA: Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol 1981;240:H149–H155.
Fulton RM, Hutchinson EC, Jones AM: Ventricular weight in cardiac hypertrophy. Br Heart J 1952;14:413–420.
Hislop A, Reid L: Arterial changes in Crotalaria spectabilis-induced pulmonary hypertension in rats. Br J Exp Pathol 1974;55:153–163.
Kay JM, Harris P, Heath D: Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds. Thorax 1967;22:176–179.
Gibson S, Miller HRP: Mast cell subsets in the rat distinguished immunohistochemically by their content of serine proteases. Immunology 1986;58:101–104.
Aldenborg F, Enerback L: Thymus dependence of connective tissue mast cells: A quantitative cytofluorometric study of the growth of peritoneal mast cells in normal and athymic rats. Int Arch Allergy Appl Immunol 1985;78:277–282.
Crowle PK, Reed ND: Bone marrow origin of mucosal mast cells. Int Arch Allergy Appl Immunol 1984;73:242–247.
Steffen M, Abboud M, Potter GK, Yung YP, Moore MA: Presence of tumor necrosis factor or a related factor in human basophil/mast cells. Immunol 1989;66:445–450.
Needleman BW, Choi J, Burrows-Mezu A, Fontana JA: Secretion and binding of transforming growth factor β by scleroderma and normal dermal fibroblasts. Arthritis Rheum 1990;33:650–656.
Gruschwitz M, Muller PU, Sepp N, Hofer E, Fontana A, Wick G: Transcription and expression of transforming growth factor type β in the skin of progressive systemic sclerosis: A mediator of fibrosis? J Invest Dermatol 1990;94:197–203.
Broekelmann TJ, Limper AH, Colby TV, McDonald JA: Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642–6646.
Cairns JA, Walls AF: Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest 1997;99:1313–1321.
Fujita J, Nakayama H, Onuoe H, Nakakura Y, Nakano T, Asai H, Takeda S, Honjo T, Kitamura Y: Fibroblast-dependent growth of mouse mast cells in vitro: Duplication of mast cell depletion in mutant mice of W/Wv genotype. J Cell Physiol 1988;134:78–84.
Jarboe DL, Marshall JS, Randolph TR, Kukolja A, Huff TF: The mast cell-committed progenitor. I. Description of a cell capable of IL-3-independent proliferation and differentiation without contact with fibroblasts. J Immunol 1989;142:2405–2417.
McGoon MD, Vanhoutte PM: Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 1984;74:828–833.
Pitt BR, Weng W, Steve AR, Blakely RD, Reynolds I, Davies P: Serotonin increases DNA synthesis in rat proximal and distal pulmonary artery smooth muscle cells in culture. Am J Physiol 1994;266:L178–L186.
Lee SL, Wang WW, Lanzillo JJ, Fanburg BL: Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994;266:L46–L52.
Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986;137:1735–1742.
Berthiaume Y, Boiteau P, Fick G, Kloiber R, Sinclair GD, Fong C, Poon MC, Lafreniere R: Pulmonary edema during IL-2 therapy: Combined effect of increased permeability and hydrostatic pressure. Am J Respir Crit Care Med 1995;152:329–335.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.